PXT3003是由(RS)-巴氯酚、盐酸纳曲酮和D-山梨醇低剂量固定配伍组成的复方制剂,三种主要成分均为上市多年的药物。(RS)-巴氯酚于1977年被FDA批准用于治疗不同疾病引起的骨骼肌痉挛,在中国于1998年上市;盐酸纳曲酮于1984年被FDA批准用于治疗阿片类药物和酒精依赖,在中国于2000年上市;D-山梨醇于1978年被FDA批准作为...
国家药品监督管理局-药物临床试验登记与信息公示平台登记了一项用于治疗CMT1A的临床试验,详细信息如下:本项目由天士力基因网络药物创新中心有限公司申办,拟入组1A型腓骨肌萎缩症患者176例,已在全国25家医院进行。【药物简介】PXT3003是由(RS)-巴氯酚、盐酸纳曲酮和D-山梨醇低剂量固定配伍组成的复方制剂,三种主要成分...
Mutel V, Lütjens R, Poli S. The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity. Neuropharmacology. 2017 Mar ...
PXT3003, A FIXED COMBINATION OF BACLOFEN, NALTREXONE AND SORBITOL, FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A (CMT1A): STATUS OF A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PIVOTAL PHASE III STUDY (PLEO-CMT) 来自 国家科技图书文献中心 喜欢 0 阅读量: 37 作者:...
These preliminary results in adults, where symptoms have evolved since childhood, strongly suggest there could be benefits in testing PXT-3003 in children as a preventative treatment. Because of the difficulty of arranging large scale clinical studies of rare diseases like CMT1A, the authors say ...
There is currently no approved treatment. We performed a meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression after one year under Placebo, Ascorbic Acid (AA) or PXT3003, a combination of three repurposed drugs. We observed a ...